Home > Healthcare > Biotechnology > Biotechnology R&D > Human Microbiome Market

Human Microbiome Market Trends

Report ID: GMI6538
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Human Microbiome Market Trends

The market is set to experience significant growth due to advancements in microbiome research, particularly in developing therapeutics for infectious diseases. Researchers and companies increasingly explore microbiome modulation to combat antibiotic-resistant infections and other pathogenic diseases.

For instance, In September 2024, researchers from the Mayo Clinic introduced a groundbreaking computational tool designed to analyze the gut microbiome—an intricate ecosystem of trillions of bacteria, viruses, fungi, and other microorganisms within the digestive system—to offer insights into overall health. In a study published in Nature Communications, the tool showcased an accuracy of at least 80% in distinguishing between healthy individuals and those with various diseases. This tool was developed by examining gut microbiome profiles from over 8,000 stool samples, covering a wide range of diseases, geographic locations, and demographic groups.

Furthermore, the demand for microbiome-based diagnostics and therapeutics is rising as healthcare systems adopt personalized approaches, tailoring treatments based on an individual’s microbiota. As these advancements progress, the ability to manipulate and restore microbial balance in the body will drive innovations in the pharmaceutical and healthcare sectors. Additionally, the trend toward non-invasive testing and microbiome sequencing will further support market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global human microbiome industry was valued at USD 842.4 million in 2023 and is expected to grow at a CAGR of 25.7% from 2024 to 2032, driven by increasing interest in the role of microbiota in health and disease.

The digestive tract segment dominated the market with a 31.7% share in 2023 due to the gut microbiomes critical role in digestion, immunity, and overall health, making it a primary target for microbiome-based therapeutics.

The North America human microbiome market reached USD 261.2 million in 2023 and is expected to demonstrate a 24.9% CAGR through 2032, attributed to the presence of major pharmaceutical companies, extensive research infrastructure, and growing investment in microbiome-based therapeutics.

Key players in the industry include 4D Pharma plc, Synlogic, Microbiome Therapeutics LLC, Enterome, Metabiomics Corporation, Seres Therapeutics, Second Genome Inc., Vedanta Biosciences, Inc., Synthetic Biologics, Inc., and DuPont.